Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators

Smart overview of the Invention

The patent application focuses on serotonin receptor agonist compounds, both hallucinogenic and non-hallucinogenic, and their use in treating and preventing various human conditions. These compounds have potential applications in addressing psychological or mood disorders such as depression, anxiety, compulsion, and PTSD.

Background

Many individuals suffer from mood disorders linked to altered synaptic connectivity in the brain. Psychedelic drugs like psilocybin and LSD have shown promise in clinical trials for alleviating symptoms of depression and PTSD by promoting neuroplasticity through 5-HT2A receptor signaling. However, these treatments are limited by their hallucinogenic nature, necessitating administration under medical supervision, and potential cardiotoxicity due to strong effects on the 5-HT2B receptor.

Summary of Invention

The disclosed invention introduces compounds of Formula I that serve as serotonin receptor agonists. These compounds aim to provide therapeutic benefits similar to traditional psychedelics without the associated hallucinogenic effects or cardiotoxic risks. The compounds can be administered safely outside clinical settings, providing more accessible treatment options for patients.

Composition and Methods

The application outlines various compositions comprising a compound of Formula I alongside an excipient or pharmaceutically acceptable carrier. It also describes methods for preventing or treating psychological disorders by administering these compounds. Additionally, the invention includes compositions combining a compound of Formula I with another active serotonergic compound.

Applications

Beyond psychological disorders, the patent also covers methods for treating inflammation and pain using these compounds. The versatility of Formula I compounds extends to various formulations and combinations, broadening their therapeutic potential across different medical conditions.